Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user considering a hair transplant with BlueMagic Group and seeking real experiences and advice. Users suggest verifying who performs the surgery, looking for long-term results, and ensuring thorough communication before proceeding.

The conversation is about someone seeking advice on the best microneedling device to use for hair loss, mentioning pens, stamps, and rollers as options.

The user is unhappy with the results of a FUT hair transplant from 2021, noting uneven hair texture and persistent thinning. They are considering a FUE procedure and have been using finasteride for a year, previously used minoxidil, and currently use Toppik for concealment.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

A 21-year-old is experiencing hair loss and is unsure whether to choose minoxidil or finasteride. They prefer oral treatments and are leaning towards finasteride despite concerns about side effects and family opposition.

A 30-year-old is seeking advice on hair loss treatment, currently using oral minoxidil, finasteride, mesotherapy, and a supplement. They are experiencing shedding and are anxious about the effectiveness of the treatment, asking if they should continue or consider other options like topicals or microneedling.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation is about someone considering a hair transplant due to ineffective hair loss treatments, with suggestions ranging from trying a hairpiece to continuing with medications like finasteride and minoxidil, and waiting for new treatments. Some advise against a transplant due to the extent of hair loss and the cost, while others share different views on the effectiveness of transplants and non-surgical options.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Users find ChatGPT a helpful tool for researching these treatments.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation is about hair regrowth using high-dose dutasteride, oral minoxidil, and microneedling. Users discuss seeing tiny hairs and hope they will become terminal, with advice to use derma rolling weekly for better results.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

An 18-year-old is maintaining a stable hairline using Minoxidil, topical finasteride (Fynzur), and Dermastamp, and is considering adding oral finasteride for prevention. They seek advice on whether starting oral finasteride early is necessary given their family history and current regimen.

Dutasteride mesotherapy, combined with peptides and exosomes, is being considered for hair loss treatment. One user suggests that oral finasteride or dutasteride mesotherapy may not be necessary if already taking oral dutasteride.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Fenugreek has mixed reviews for hair loss, with some reporting success and others experiencing worsening conditions. Few people have shared their experiences online.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user has been using finasteride for over a year, which improved their hairline but not the crown area. They are considering alternatives like hair fibers, derma stamping, or possibly minoxidil, while avoiding topicals due to their work environment.

A user is treating their advanced hair loss with a regimen including topical finasteride, minoxidil, hydrocortisone, stem cell serum, peptide serum, multivitamins, he shou wu tea, derma pen, argan oil, and a derma roller. Replies suggest it's too early to judge progress and recommend staying consistent, with one suggesting oral minoxidil as an additional option.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.

Six months after a 4000 graft hair transplant, the individual has seen little to no results. They are currently using finasteride, minoxidil, ketoconazole, and biotin but not microneedling. The advice given is to wait another 2-6 months as full results can take up to a year, and to consider the possibility of shock loss.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.